SCHEMBL721470

SCHEMBL721470

Cc1c(C(=O)CC(C)C)oc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.62
SMN1; SMN2 Q16637 5/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
HTT P42858 2/20 0.50
RECQL P46063 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 1/20 0.49
HCRTR1 O43613 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 1/20 0.48
KDM4E B2RXH2 1/20 0.48
AHR P35869 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7030842 0.82 KCNH2 (0.68) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL879305 0.82 KCNH2 (0.59) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL12820358 0.81 KCNH2 (0.66) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL719538 0.81 KCNH2 (0.66) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL11724394 0.77 KCNH2 (1.00) KCNH2NPC1RAB9AHTTRECQL
SCHEMBL442779 0.76 MCL1 (0.60) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL114250 0.76 KMT2A (0.60) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL25472764 0.75 KCNH2 (0.58) KCNH2SMN1; SMN2NPC1RAB9AHTT
Hydrochloric Acid SCHEMBL9789912 0.75 MCL1 (0.58) KCNH2SMN1; SMN2NPC1RAB9AHTT
SCHEMBL992866 0.75 KCNH2 (0.58) KCNH2SMN1; SMN2NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KCNH2 2392/4885SMN1; SMN2 1051/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KCNH2 2392/4885SMN1; SMN2 1051/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.